Evidence map›Paper›PMID 37328638›Full record

ArticleVirus genes2023

Preparation of monoclonal antibodies against Epstein-Barr virus glycoprotein 350.

Jiao Zheng, Xuan Zeng, Linxiu Zeng, Ye Xu, Zhihong Zhong, Yi Wu, Yilan Qiu, Rushi Liu

Abstract read
PubMed Publisher
In one paragraph

Article in Virus genes, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Jiao ZhengSchool of Medicine, Hunan Normal University, Changsha, China.
Xuan ZengImmunodiagnostic Reagents Engineering Research Center of Hunan Province, Hunan Normal University, Changsha, China.
Linxiu ZengSchool of Medicine, Hunan Normal University, Changsha, China.
Ye XuHunan Xuxiang Biotechnology Co., Ltd., Changsha, China.
Zhihong ZhongSchool of Medicine, Hunan Normal University, Changsha, China.
Yi WuThe First Affiliated Hospital of Hunan Normal University, Changsha, China.
Yilan QiuCollege of Life Science, Hunan Normal University, Changsha, China. qiu730822@163.com.
Rushi LiuSchool of Medicine, Hunan Normal University, Changsha, China. liurushi@hunnu.edu.cn.
Hunan Normal University · CN

Funding

Hunan Provincial Natural Science Foundation of China No. 2019JJ50370Key R&D Program of Hunan Province No. 2019SK2042National Natural Science Foundation of China No. 31072141
6 · The paper itself

Abstract

Epstein-Barr virus (EBV) is the first identified human oncogenic herpesvirus infecting over 90% of the adults worldwide. However, the safe and effective prophylactic vaccine has not been licensed. The major glycoprotein 350 (gp350) on the EBV envelope is the main target for neutralizing antibodies, and gp350 (aa15-320) was used for the development of monoclonal antibodies in present study. The purified recombinant gp350

Indexed as

Epstein-Barr Virus InfectionsHerpesvirus 4, HumanAdultAnimalsAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralGlycoproteinsHumansMiceAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralGlycoproteinsEpitopeEpstein-Barr virus (EBV)Glycoprotein 350Infection-blockingMonoclonal antibody

Identifiers

PMID37328638
OpenAlexW4380989511

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.